A Phase 1 Study of Resiniferatoxin for Severe Cancer Pain
Recruiting Phase 1 NCT00804154
Study Description
Evaluating the Safety of Resiniferatoxin in Treating Severe Pain in Advanced Cancer Patients
Study Details
- Registry ID:
- NCT00804154
- Conditions:
- Intractable Pain, Palliative Care
- Phase:
- Phase 1
- Target Enrollment:
- 45 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (1 site)
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.